Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=other_investigators" }, "data": [ { "type": "Grant", "id": "10587", "attributes": { "award_id": "3U54CA260492-02S1", "title": "Admin-Core-001", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 23484, "first_name": "Lillian S.", "last_name": "Kuo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2025-08-31", "award_amount": 119719, "principal_investigator": { "id": 23616, "first_name": "ANDREA L", "last_name": "COX", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22942, "first_name": "SABRA L.", "last_name": "KLEIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Johns Hopkins has broad expertise in the science of human health, with viral immunity, pathogenesis, epidemiology, biostatistics, and surveillance emerging as integral components of the multidisciplinary research mounted at Johns Hopkins during the current pandemic. We propose development of a Serological Sciences Center of Excellence: the Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2 (JH-EPICS). The overarching goal of JH-EPICS is to distinguish immune responses that protect from those that cause pathology during infection. Under the Multiple PI leadership of Drs. Klein and Cox, the JH-EPICS Administrative Core will ensure resources and samples are available to systematically evaluate innate, T cell, and antibody responses to SARS-CoV-2 in peripheral blood mononuclear cells and serological samples from COVID-19 patients sampled longitudinally. JH-EPICS contains three interconnecting Research Projects (RPs). RP1 focuses on innate immune sensing and activation of the human inflammasome by SARS-CoV-2, with evaluation of how anti-SARS-CoV-2 antibodies modulate innate sensing. RP2 uses a novel flow-cytometry based platform that enables single cell analysis of traditional cell surface markers combined with intracellular staining for proteins involved in metabolic programming. Using this platform, we have identified distinct myeloid derived suppressor cells (MDSCs) and T cells abundant in COVID-19. RP1 will characterize these MDSCs, while RP2 will explore novel populations of T cells identified in COVID-19 patients. RP2 will also define novel biomarkers in order to predict severity of disease, track the course of disease, and define novel surrogate markers for testing therapeutic regimens. Together, RP1 and RP2 will identify novel therapeutic targets. In RP3, the magnitude, duration, and class switching of SARS-CoV-2-specific antibody isotypes as well as virus- specific neutralizing antibody responses will be analyzed and compared with non-neutralizing antibody functions, e.g., complement fixation and antibody-dependent cellular cytotoxicity, using a novel core set of serological assays. A centralized Virology Reagent Core will provide antigen for ELISAs, reagents to identify virus-specific immune cell populations, inactivated SARS-CoV-2 viruses, methods for quantifying SARS-CoV- 2, and access to biosafety level 3 facilities and training needed to perform any experiments involving live SARS-CoV-2. The Analysis Resource Core will provide statistical modeling and analysis to frame and test hypotheses about the mechanisms mediating the severity of COVID-19 as well as the intersectionality of sex, gender, age, and racial differences in immune mechanisms of COVID-19. In concert with the trans-network collaborations, this research will provide significant insights into pathologic immune responses to SARS-CoV-2, identification of novel therapeutic targets, and definition of immunity against SARS-CoV-2 infection. By uncovering the correlates of protective immunity, JH-EPICS research will further enhance vaccine design and evaluation of vaccine candidates.", "keywords": [ "2019-nCoV", "Address", "Affect", "Age", "Antibodies", "Antibody Response", "Antigens", "Basic Science", "Biometry", "COVID-19", "COVID-19 patient", "COVID-19 severity", "Cell surface", "Cells", "Cessation of life", "Clinical", "Clinical Sciences", "Collaborations", "Communicable Diseases", "Complement", "Complex", "Coupled", "Data Analyses", "Development", "Diabetes Mellitus", "Disease", "Ensure", "Enzyme-Linked Immunosorbent Assay", "Epidemiologic Monitoring", "Epidemiology", "Ethnic Origin", "Evaluation", "Flow Cytometry", "Foundations", "Gender", "Goals", "HIV", "Health", "Healthcare Systems", "Heart Diseases", "Human", "Immune", "Immune response", "Immunity", "Immunoglobulin Class Switching", "Immunology", "Immunomodulators", "Infant", "Infection", "Inflammasome", "Inflammatory Response", "Infrastructure", "Interdisciplinary Study", "International", "Leadership", "Mediating", "Metabolic", "Methods", "Mission", "Modeling", "Monoclonal Antibody Therapy", "Myeloid-derived suppressor cells", "Organ Transplantation", "Outcome", "Pathogenesis", "Pathologic", "Pathology", "Patients", "Peripheral Blood Mononuclear Cell", "Persons", "Population", "Prospective cohort", "Proteins", "Protocols documentation", "Public Health", "Race", "Reagent", "Regimen", "Reporting", "Research", "Research Activity", "Research Personnel", "Research Project Grants", "Resources", "Respiratory Tract Infections", "Risk", "SARS-CoV-2 antibody", "SARS-CoV-2 immune response", "SARS-CoV-2 immunity", "SARS-CoV-2 infection", "Sampling", "Science", "Serology", "Serology test", "Severity of illness", "Sex Differences", "Solid", "Stains", "Statistical Data Interpretation", "Statistical Models", "Surrogate Markers", "Symptoms", "T-Lymphocyte", "Testing", "Therapeutic", "Training", "Translational Research", "Ursidae Family", "Vaccine Design", "Viral", "Viral Pathogenesis", "Virus", "age difference", "antibody-dependent cell cytotoxicity", "base", "biosafety level 3 facility", "comorbidity", "experimental study", "gender difference", "innate immune sensing", "insight", "intersectionality", "male", "neutralizing antibody", "new therapeutic target", "novel", "novel marker", "pandemic disease", "racial difference", "rational design", "response", "sample fixation", "severe COVID-19", "sex", "single cell analysis", "therapeutic evaluation", "therapy development", "vaccine candidate", "vaccine development", "vaccine eva" ], "approved": true } }, { "type": "Grant", "id": "7155", "attributes": { "award_id": "3R01DA043396-04S1", "title": "Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 22949, "first_name": "Raul N", "last_name": "Mandler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-15", "end_date": "2022-05-31", "award_amount": 154500, "principal_investigator": { "id": 22950, "first_name": "Shyamasundaran", "last_name": "Kottilil", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 793, "ror": "", "name": "UNIVERSITY OF MARYLAND BALTIMORE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22951, "first_name": "Bhawna", "last_name": "Poonia", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 793, "ror": "", "name": "UNIVERSITY OF MARYLAND BALTIMORE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Risk factors for developing severe illness/acute respiratory distress syndrome from coronavirus disease 2019 (COVID-19) include older age, male gender, and underlying conditions, currently identified as smoking, chronic lung disease or moderate to severe asthma, heart disease with complications, severe obesity, diabetes, renal failure or liver disease. Immune factors are likely to contribute to disease progression. While immune activation is required for anti-viral response, severely ill patients show an excessive and aberrant host immune response as evidenced by high inflammatory markers and proinflammatory cytokines. On the other hand, factors associated with less robust immune response against the virus, such as advanced age are associated with severe disease. Opioid use disorder (OUD) is an important public heath condition associated with dysregulated immunity. This may be related to higher prevalence of systemic comorbid conditions and concomitant conditions like chronic HIV, hepatitis C or incident infections related to injection drug use, which may further influence immune response to infections. An especially vulnerable group is people living with HIV (PLWH) with OUD, which are expected to have further immune dysregulations due to twin effect of HIV and opioids on immunity. Additionally, people with OUD are at increased risk of COVID-19 due to social factors such as homelessness, poor access to healthcare, housing insecurity, greater likelihood of incarceration, which can make it more difficult to maintain social distancing and these individuals may not seek medical care promptly due to lack of access to outpatient care. We are asking whether OUD constitutes a risk factor for progressive (COVID-19), especially in PLWH. We are investigating immune responses in individuals with OUD and HIV infection under our NIDA funded R01; leveraging the clinical cohorts and IRB approved blood collection protocols from COVID-19 patients, here we will investigate incidence and progression of COVID-19 in these patient populations. First, we will document clinical course and outcomes of COVID-19 in patients with or without OUD/HIV. To identify immune correlates of COVID-19 severity, we will perform analysis of B and T cell responses and study impact of OUD and HIV on this response. Our investigation of clinical and immunological features of the disease in PLWH and OUD will expand on known correlates of progressive COVID-19 and will inform treatment and prophylactic approaches for COVID-19 in vulnerable groups.", "keywords": [ "2019-nCoV", "Acute", "Adult Respiratory Distress Syndrome", "Affect", "Age", "Ambulatory Care", "Antiviral Response", "Area", "Asthma", "B-Lymphocytes", "Blood", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "COVID-19", "Cancer Patient", "Caring", "Case Study", "Chronic", "Chronic lung disease", "Classification", "Clinical", "Clinical Protocols", "Collection", "Diabetes Mellitus", "Disease", "Disease Progression", "Elderly", "Enrollment", "Funding", "Gender", "Generations", "Goals", "HIV", "HIV Infections", "HIV/HCV", "Heart Diseases", "Helper-Inducer T-Lymphocyte", "Hepatitis C", "High Prevalence", "Homelessness", "Housing", "Human", "Immune", "Immune response", "Immune system", "Immunity", "Immunoglobulin G", "Immunoglobulin M", "Immunologic Factors", "Immunologics", "Immunosuppression", "Impairment", "Imprisonment", "Incidence", "Individual", "Infection", "Injecting drug user", "Institutes", "Institutional Review Boards", "Investigation", "Kidney Failure", "Laboratories", "Liver diseases", "Mediator of activation protein", "Medical", "Monitor", "Morbid Obesity", "National Institute of Allergy and Infectious Disease", "National Institute of Drug Abuse", "Opioid", "Outcome", "Patients", "Peripheral Blood Mononuclear Cell", "Persons", "Pneumonia", "Production", "Progressive Disease", "Protocols documentation", "Recovery", "Research", "Resolution", "Risk", "Risk Factors", "Sampling", "Serum", "Severities", "Severity of illness", "Smoker", "Smoking", "Social Distance", "Substance abuse problem", "Syndrome", "T cell response", "T-Cell Activation", "Twin Multiple Birth", "United States National Institutes of Health", "Virus", "Virus Diseases", "Vulnerable Populations", "adaptive immunity", "arm", "base", "clinical investigation", "cohort", "comorbidity", "cytokine", "cytokine release syndrome", "exhaustion", "health care availability", "high risk", "immune activation", "inflammatory marker", "injection drug use", "interest", "male", "opioid abuse", "opioid use disorder", "patient population", "patient subsets", "primary outcome", "prophylactic", "response", "sample collection", "social factors", "success", "virology" ], "approved": true } }, { "type": "Grant", "id": "7164", "attributes": { "award_id": "3R44MD012279-03S1", "title": "Staying Connected: Community-engaged research to address the impacts of the COVID-19 Pandemic among transgender women through an m-health prevention program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 22838, "first_name": "SIMRANN KAUR", "last_name": "Sidhu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-21", "end_date": "2021-09-30", "award_amount": 178455, "principal_investigator": { "id": 22957, "first_name": "CHARLES Howard", "last_name": "KLEIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1549, "ror": "", "name": "DFUSION, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22958, "first_name": "Tamara J", "last_name": "Kuhn", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22959, "first_name": "Christina Jiayi", "last_name": "Sun", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1549, "ror": "", "name": "DFUSION, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "ABSTRACT: Staying Connected: Community-engaged research to address the impacts of the COVID-19 Pandemic among transgender women through an mhealth prevention program The COVID-19 pandemic has reminded the world that viral outbreaks are a reality and can quickly generate high levels of mortality and morbidity, overwhelm health-care systems, and produce massive social and economic upheaval. Epidemiological data suggest that COVID-19 will have its most devastating impact on the most vulnerable members of society, and in the process, exacerbate existing health disparities. In the United States, transgender women, and in particular transgender women of color, are particularly at risk for COVID-19 infection due to high levels of HIV infection, substance abuse, depression, anxiety disorders, and social isolation. Research demonstrates that these health disparities and vulnerabilities are connected to the multiple forms of discrimination that shape transgender women’s lives. In this context, the COVID-19 pandemic and accompanying mitigation strategies affect not only COVID-19 transmission and disease, but also transgender women’s adherence to HIV anti-retroviral therapies, utilization of the HIV prevention continuum, financial and housing stability, and anxiety and depression associated with the disruption of gender-affirming care. This proposed administrative supplement will build on our current project, Trans Women Connected (TWC), an mhealth sexual health promotion app for transgender women, by conducting research to gain greater understanding of and ways to respond to these inter-connected and still evolving trans-specific COVID-19 impacts. Specifically, we aim to: 1) Conduct rapid formative research to examine the impact of COVID-19 and mitigation strategies, including unintended negative consequences, on transgender women through focus groups, expert advisors, and an engaged community advisory board; 2) Develop a culturally tailored, community- strengths and cognitive behavior theory informed module of interactive COVID-19 educational activities for integration into the overall TWC mobile app. The skills-building activities seek to support COVID-19 mitigation strategies, reduce COVID-19 morbidity and mortality, and in general, improve health care utilization, increase self-care and resilience, and promote connectedness among transgender women, thereby leading to improved overall mental and physical health; and 3) Evaluate the impact of the COVID-19 module as part of the larger parent grant 2-arm cluster randomized controlled trial with 450 transgender women. This evaluation will enable us to collect data on COVID-19 and the impact of the mhealth module on transgender women over a 12-month time period likely encompassing relaxation of distancing measures, possible second and third waves of infections and additional periods of lockdown, and potentially, the emergence of a vaccine. The project offers the possibility of unprecedented insights into effects of the COVID-19 pandemic on the health, connectedness, and behaviors of one of the most vulnerable and socially marginalized populations in the US.", "keywords": [ "AIDS prevention", "Address", "Adherence", "Administrative Supplement", "Affect", "Anxiety", "Anxiety Disorders", "Behavior", "COVID-19", "COVID-19 pandemic", "Caring", "Cognitive", "Color", "Communities", "Data", "Discrimination", "Disease", "Disease Outbreaks", "Economics", "Educational Activities", "Evaluation", "Focus Groups", "Gender", "HIV Infections", "HIV antiretroviral", "Health", "Health Promotion", "Healthcare Systems", "Housing", "Infection", "Intervention", "Measures", "Mental Depression", "Mental Health", "Morbidity - disease rate", "Population", "Prevention program", "Process", "Public Health", "Randomized Controlled Trials", "Relaxation", "Research", "Risk", "Self Care", "Sexual Health", "Shapes", "Social isolation", "Societies", "Substance abuse problem", "Time", "United States", "Vaccines", "Viral", "antiretroviral therapy", "arm", "cost effective", "effective intervention", "epidemiologic data", "health care service utilization", "health disparity", "improved", "insight", "mHealth", "member", "mobile application", "mortality", "parent grant", "physical conditioning", "resilience", "skills", "social", "theories", "transgender women", "transmission process", "uptake" ], "approved": true } }, { "type": "Grant", "id": "7164", "attributes": { "award_id": "3R44MD012279-03S1", "title": "Staying Connected: Community-engaged research to address the impacts of the COVID-19 Pandemic among transgender women through an m-health prevention program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 22838, "first_name": "SIMRANN KAUR", "last_name": "Sidhu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-21", "end_date": "2021-09-30", "award_amount": 178455, "principal_investigator": { "id": 22957, "first_name": "CHARLES Howard", "last_name": "KLEIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1549, "ror": "", "name": "DFUSION, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22958, "first_name": "Tamara J", "last_name": "Kuhn", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22959, "first_name": "Christina Jiayi", "last_name": "Sun", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1549, "ror": "", "name": "DFUSION, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "ABSTRACT: Staying Connected: Community-engaged research to address the impacts of the COVID-19 Pandemic among transgender women through an mhealth prevention program The COVID-19 pandemic has reminded the world that viral outbreaks are a reality and can quickly generate high levels of mortality and morbidity, overwhelm health-care systems, and produce massive social and economic upheaval. Epidemiological data suggest that COVID-19 will have its most devastating impact on the most vulnerable members of society, and in the process, exacerbate existing health disparities. In the United States, transgender women, and in particular transgender women of color, are particularly at risk for COVID-19 infection due to high levels of HIV infection, substance abuse, depression, anxiety disorders, and social isolation. Research demonstrates that these health disparities and vulnerabilities are connected to the multiple forms of discrimination that shape transgender women’s lives. In this context, the COVID-19 pandemic and accompanying mitigation strategies affect not only COVID-19 transmission and disease, but also transgender women’s adherence to HIV anti-retroviral therapies, utilization of the HIV prevention continuum, financial and housing stability, and anxiety and depression associated with the disruption of gender-affirming care. This proposed administrative supplement will build on our current project, Trans Women Connected (TWC), an mhealth sexual health promotion app for transgender women, by conducting research to gain greater understanding of and ways to respond to these inter-connected and still evolving trans-specific COVID-19 impacts. Specifically, we aim to: 1) Conduct rapid formative research to examine the impact of COVID-19 and mitigation strategies, including unintended negative consequences, on transgender women through focus groups, expert advisors, and an engaged community advisory board; 2) Develop a culturally tailored, community- strengths and cognitive behavior theory informed module of interactive COVID-19 educational activities for integration into the overall TWC mobile app. The skills-building activities seek to support COVID-19 mitigation strategies, reduce COVID-19 morbidity and mortality, and in general, improve health care utilization, increase self-care and resilience, and promote connectedness among transgender women, thereby leading to improved overall mental and physical health; and 3) Evaluate the impact of the COVID-19 module as part of the larger parent grant 2-arm cluster randomized controlled trial with 450 transgender women. This evaluation will enable us to collect data on COVID-19 and the impact of the mhealth module on transgender women over a 12-month time period likely encompassing relaxation of distancing measures, possible second and third waves of infections and additional periods of lockdown, and potentially, the emergence of a vaccine. The project offers the possibility of unprecedented insights into effects of the COVID-19 pandemic on the health, connectedness, and behaviors of one of the most vulnerable and socially marginalized populations in the US.", "keywords": [ "AIDS prevention", "Address", "Adherence", "Administrative Supplement", "Affect", "Anxiety", "Anxiety Disorders", "Behavior", "COVID-19", "COVID-19 pandemic", "Caring", "Cognitive", "Color", "Communities", "Data", "Discrimination", "Disease", "Disease Outbreaks", "Economics", "Educational Activities", "Evaluation", "Focus Groups", "Gender", "HIV Infections", "HIV antiretroviral", "Health", "Health Promotion", "Healthcare Systems", "Housing", "Infection", "Intervention", "Measures", "Mental Depression", "Mental Health", "Morbidity - disease rate", "Population", "Prevention program", "Process", "Public Health", "Randomized Controlled Trials", "Relaxation", "Research", "Risk", "Self Care", "Sexual Health", "Shapes", "Social isolation", "Societies", "Substance abuse problem", "Time", "United States", "Vaccines", "Viral", "antiretroviral therapy", "arm", "cost effective", "effective intervention", "epidemiologic data", "health care service utilization", "health disparity", "improved", "insight", "mHealth", "member", "mobile application", "mortality", "parent grant", "physical conditioning", "resilience", "skills", "social", "theories", "transgender women", "transmission process", "uptake" ], "approved": true } }, { "type": "Grant", "id": "7165", "attributes": { "award_id": "3U01HG006379-09S1", "title": "Genomic Basis of Susceptibility to COVID-19 Infection and its Complications", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Human Genome Research Institute (NHGRI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22881, "first_name": "ROBB KENNETH", "last_name": "Rowley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2011-08-15", "end_date": "2025-04-30", "award_amount": 282848, "principal_investigator": { "id": 22960, "first_name": "Iftikhar J", "last_name": "Kullo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1426, "ror": "", "name": "MAYO CLINIC ROCHESTER", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22961, "first_name": "Richard R.", "last_name": "Sharp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1426, "ror": "", "name": "MAYO CLINIC ROCHESTER", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "In addition to causing millions of cases and hundreds of thousands of deaths, the Coronavirus disease 2019 (COVID-19) pandemic has brought life and economic activity to a near standstill in many parts of the world. A coordinated scientific effort is necessary to mitigate the widespread misery, morbidity and mortality inflicted by the pandemic. The goal of this supplemental application is to contribute to informatics and genomics efforts to identify the genomic basis of susceptibility to and complications of COVID-19. The wide spectrum of disease severity with COVID-19 is only partially explained by age and medical comorbidities and genetic factors are likely to play a key role. Identifying genomic factors impacting COVID-19 case status and complications is important for risk stratification, identifying new pathophysiologic pathways for drug development/repurposing, and improved understanding of the biology of SARS-CoV-2 infection and its complications. As part of the electronic Medical Records and Genomics (eMERGE) since its inception in 2007, Mayo investigators have considerable experience in using the electronic health record (EHR) for genomics research. We will develop electronic phenotyping algorithms to ascertain COVID-19 case status, complications and fatality, to identify genomic variants associated with adverse outcomes. Using DNA samples linked to the EHR, we will perform genomic analyses to identify common and rare variants associated with case status, case severity and case mortality. We will collaborate with health systems and consortia in the US and around the world to increase the power and rapidity of the genomic studies. Our specific aims are: Specific Aim 1: Develop and validate electronic phenotyping algorithms to ascertain COVID-19 related phenotypes including case control status, i.e., individuals tested and those were identified to be positive for COVID-19, and disease severity, in particular cardiovascular complications including myocardial injury/infarction, arrhythmias, coagulopathy as well as large vessel thrombosis. Specific Aim 2: Perform genomic association analyses to identify variants associated with susceptibility to infection with SARS-CoV-2 and its complications. We will compare test +ve vs test -ve individuals, mild vs hospitalized cases of COVID-19 and among the latter those who develop severe disease or die. In addition to genome-wide association studies (GWAS), we will conduct association studies of the HLA region and burden tests using sequence data.", "keywords": [ "2019-nCoV", "ABO blood group system", "Affect", "Age", "American Heart Association", "Arrhythmia", "Biology", "Blood Coagulation Disorders", "COVID-19", "COVID-19 pandemic", "Cardiovascular system", "Cessation of life", "Computerized Medical Record", "Cytokine Receptors", "DNA", "Data", "Disease", "Economics", "Electronic Health Record", "Electronic Medical Records and Genomics Network", "Genes", "Genetic", "Genomic approach", "Genomics", "Goals", "HLA Antigens", "Health system", "Individual", "Infarction", "Infection", "Inflammasome", "Informatics", "Life", "Link", "Medical", "Molecular", "Morbidity - disease rate", "Natural Immunity", "Participant", "Pathway interactions", "Patients", "Pattern", "Phenotype", "Play", "Positioning Attribute", "Predisposing Factor", "Predisposition", "Registries", "Research", "Research Personnel", "Risk stratification", "Sampling", "Severities", "Severity of illness", "Signal Pathway", "Site", "Susceptibility Gene", "Testing", "Thrombosis", "Translating", "United States National Institutes of Health", "Variant", "Virus Diseases", "Work", "adaptive immunity", "adverse outcome", "biobank", "case control", "comorbidity", "coronavirus disease", "cytokine", "cytokine release syndrome", "drug development", "experience", "genetic variant", "genome wide association study", "genomic data", "implementation science", "improved", "improved outcome", "interest", "mortality", "myocardial injury", "novel", "pandemic disease", "pathogen", "patient registry", "phenotyping algorithm", "polygenic risk score", "rare variant", "response" ], "approved": true } }, { "type": "Grant", "id": "7173", "attributes": { "award_id": "3P50MD010428-05S1", "title": "Disparities in Exposure and Health Effects of Multiple Environmental Stressors Across the Life Course", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6598, "first_name": "Deborah Elizabeth", "last_name": "Linares", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2015-07-24", "end_date": "2021-08-31", "award_amount": 221125, "principal_investigator": { "id": 22966, "first_name": "Francine", "last_name": "Laden", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 961, "ror": "", "name": "HARVARD SCHOOL OF PUBLIC HEALTH", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22967, "first_name": "Jonathan I", "last_name": "Levy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 961, "ror": "", "name": "HARVARD SCHOOL OF PUBLIC HEALTH", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The primary objective of our Center is to understand and reduce environmental health disparities (EHDs) by conducting three fully-integrated research projects applying novel methods in epidemiology, exposure science, and cumulative risk assessment, with strong community engagement across the Center. The Center emphasizes multiple health outcomes across the life course with evidence for EHDs (birth outcomes, childhood growth rates, and cardiovascular mortality), in Massachusetts and within two low-income majority-minority communities (Chelsea and Dorchester). The influence of housing and the neighborhood environment on multiple exposures and health outcomes are emphasized throughout the Center. Within Project 3, we use novel geospatial data and simulation techniques to provide an extensive and highly resolved set of chemical and non-chemical stressor exposures, including spatially-resolved air pollution and temperature data generated in Project 1. In this supplement, we will leverage our Project 3 geospatial database of numerous social, housing, demographic, and environmental exposures across Massachusetts to evaluate racial/ethnic disparities in COVID-19 cases, hospitalizations, and deaths. Our geospatial vulnerability data will be linked with individual-level COVID-19 data with address-level geocodes and daily temporal resolution, provided by the Massachusetts Department of Public Health. We will identify vulnerability factors associated with disparities in incidence and severity of COVID-19 infection across cities and towns in Massachusetts, modeling predictors of case incidence per 10,000 persons and hospitalizations per 10,000 persons by city/town over time. We will also apply novel methods to characterize spatiotemporal clustering, allowing us to determine differences in spatiotemporal patterns of COVID-19 spread within and between cities/towns, including as a function of individual characteristics. Finally, we will examine differences in city/town-specific policies, implementation of state policy, and resident perception of public health recommendations, to determine if observed patterns can be explained in part by between-city differences. With these analyses we will identify COVID-19 hot spots in Massachusetts and how cases spread within and between communities, including the hardest-hit majority-minority communities, and we will determine the vulnerability factors that best explain these exposure and health outcome disparities.", "keywords": [ "Address", "African American", "Air Pollution", "Area", "Birth", "COVID-19", "COVID-19 pandemic", "Cardiovascular system", "Cessation of life", "Characteristics", "Chemicals", "Childhood", "Cities", "Communicable Diseases", "Communities", "Data", "Data Set", "Databases", "Disease Outbreaks", "Environment", "Environmental Exposure", "Environmental Health", "Epidemiology", "Ethnic Origin", "Future", "Geography", "Growth", "Health", "Health care facility", "High Prevalence", "Hispanics", "Home environment", "Hospitalization", "Hot Spot", "Housing", "Incidence", "Individual", "Infection", "Intervention", "Knowledge", "Leadership", "Life Cycle Stages", "Link", "Long-Term Care", "Low income", "Masks", "Massachusetts", "Methods", "Minority", "Neighborhoods", "New Jersey", "New York", "Not Hispanic or Latino", "Occupational Exposure", "Outcome", "Pattern", "Perception", "Persons", "Physical environment", "Plant Roots", "Play", "Policies", "Population", "Prevalence", "Prevention strategy", "Public Health", "Race", "Recommendation", "Research", "Research Project Grants", "Risk Assessment", "Risk Factors", "Role", "Science", "Severities", "Severity of illness", "Social Environment", "Techniques", "Temperature", "Time", "United States", "Vulnerable Populations", "Work", "adverse outcome", "base", "built environment", "comorbidity", "density", "disparity reduction", "environmental stressor", "ethnic minority population", "geographic difference", "health disparity", "health economics", "infection rate", "minority communities", "mortality", "novel", "pandemic disease", "population health", "predictive modeling", "racial and ethnic", "racial and ethnic disparities", "segregation", "simulation", "social", "social stressor", "sociodemographics", "spatiotemporal", "stressor", "temporal measurement", "transmission process" ], "approved": true } }, { "type": "Grant", "id": "7174", "attributes": { "award_id": "3U54EB027690-03S2", "title": "Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 6433, "first_name": "Tiffani Bailey", "last_name": "Lash", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-30", "end_date": "2022-05-31", "award_amount": 7085000, "principal_investigator": { "id": 15708, "first_name": "Oliver", "last_name": "Brand", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22968, "first_name": "Wilbur A", "last_name": "Lam", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22969, "first_name": "GREGORY S", "last_name": "MARTIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The advent of point-of-care (POC) diagnostic capabilities has enabled rapid and timely clinical evaluation in the physician's office, an ambulance, the home, the field, or in the hospital and has the potential to significantly impact health care delivery. In cardiology, pulmonology/critical care, and hematology, POC testing plays an especially significant role as the heart and lungs are among the most vital of organs necessitating real time diagnosis and rapid management during critical illnesses, while pathologic alternations in blood are associated with critical, systemic illness. One class of novel medical technologies that is showing promise for POC applications are microsystems-engineered technologies, that is, microchip-enabled devices ranging from microelectromechanical systems (MEMs)-based sensors, microfluidics, to even smartphone-based systems. Notable for their small size and power requirements, microchip-based systems provide the portability that is vital for POC testing. In addition, the capability of microsystems to convert sound and movement into electrical signals enable these technologies to be ideal devices to sense the dynamics of the lungs and heart and therefore to diagnose and monitor pulmonary and cardiac disorders. Moreover, microsystems engineering has brought forth the field of microfluidics, which is steadily finding applications for blood-based diagnostics, and therefore, hematologic applications. To that end, per the NHLBI's U54 POCTRN guidelines, the overall goal of the Atlanta Center for Microsystems Engineered POC Technologies (ACME POCT) is to assist and enable inventors from across the country who have developed microsystems-based POC technologies for cardiac, pulmonary, hematologic and sleep applications that are beyond proof-of-concept to define their specific clinical needs, conduct clinical validation, and refine their technology, with the objective of accelerating the path to translation and clinical adoption and directly addressing the barriers thereof. The ACME POCT uniquely leverages Atlanta's nationally top-ranked clinical programs at Emory University's hospitals and Children's Healthcare of Atlanta, one of the nation's largest pediatric hospital systems, as well the internationally acclaimed microsystems engineering expertise at Georgia Tech, which includes the Institute for Electronics and Nanotechnology (IEN), and other one-of-a-kind medical device prototyping, innovation, and testbed facilities. The ACME POCT PI's uniquely balance the engineering and clinical sides of the Center and comprise Wilbur Lam, MD, PhD, a clinical hematologist at Emory and Georgia Tech bioengineer with expertise in POC diagnostic development and commercialization, Oliver Brand, PhD, a renowned microsystems engineer and head of Georgia Tech's IEN, and Greg Martin, MD, MSc, a clinical pulmonologist at Emory and head of clinical research in Atlanta's NIH-funded CTSA. Importantly, the leadership of the ACME POCT has a history of collaboration and track record in managing Centers that have fostered medical device development.", "keywords": [ "Address", "Adoption", "Ambulances", "Bedside Testings", "Biomedical Engineering", "Blood", "Cardiac", "Cardiology", "Care Technology Points", "Cellular Phone", "Child health care", "Clinical", "Clinical Research", "Clinical and Translational Science Awards", "Clinical assessments", "Collaborations", "Country", "Critical Care", "Critical Illness", "Data", "Development", "Device or Instrument Development", "Devices", "Diagnosis", "Diagnostic", "Doctor of Philosophy", "Electronics", "Engineering", "Equilibrium", "Faculty", "Fostering", "Funding", "Future", "General Population", "Goals", "Guidelines", "Head", "Health Services Research", "Heart", "Heart Diseases", "Heart failure", "Hematologist", "Hematology", "Home environment", "Hospitals", "Institutes", "International", "Leadership", "Lung", "Lung diseases", "Medical Device", "Medical Technology", "Medicine", "Microfluidics", "Monitor", "Movement", "Nanotechnology", "National Heart Lung and Blood Institute", "Organ", "Pathologic", "Patients", "Pediatric Hospitals", "Physicians", "Physicians&apos", "Offices", "Play", "Process", "Pulmonology", "Recording of previous events", "Role", "Side", "Signal Transduction", "Sleep", "System", "Technology", "Testing", "Time", "Training Activity", "Translations", "United States National Institutes of Health", "University Hospitals", "Validation", "base", "commercialization", "cost", "health care delivery", "innovation", "microchip", "microsensor", "microsystems", "novel", "operation", "point of care", "point-of-care diagnostics", "portability", "programs", "prototype", "research clinical testing", "sensor", "sound", "success", "technology development", "technology training", "uptake", "usability" ], "approved": true } }, { "type": "Grant", "id": "9045", "attributes": { "award_id": "3U54EB027690-02S1", "title": "Emergency COVID-19 supplement for Atlanta Center for Microsystems Engineered Point-of-Care Technoloites (ACME POCT)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 6433, "first_name": "Tiffani Bailey", "last_name": "Lash", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-22", "end_date": "2021-05-21", "award_amount": 31080737, "principal_investigator": { "id": 15708, "first_name": "Oliver", "last_name": "Brand", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22968, "first_name": "Wilbur A", "last_name": "Lam", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22969, "first_name": "GREGORY S", "last_name": "MARTIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The advent of point-of-care (POC) diagnostic capabilities has enabled rapid and timely clinical evaluation in the physician's office, an ambulance, the home, the field, or in the hospital and has the potential to significantly impact health care delivery. In cardiology, pulmonology/critical care, and hematology, POC testing plays an especially significant role as the heart and lungs are among the most vital of organs necessitating real time diagnosis and rapid management during critical illnesses, while pathologic alternations in blood are associated with critical, systemic illness. One class of novel medical technologies that is showing promise for POC applications are microsystems-engineered technologies, that is, microchip-enabled devices ranging from microelectromechanical systems (MEMs)-based sensors, microfluidics, to even smartphone-based systems. Notable for their small size and power requirements, microchip-based systems provide the portability that is vital for POC testing. In addition, the capability of microsystems to convert sound and movement into electrical signals enable these technologies to be ideal devices to sense the dynamics of the lungs and heart and therefore to diagnose and monitor pulmonary and cardiac disorders. Moreover, microsystems engineering has brought forth the field of microfluidics, which is steadily finding applications for blood-based diagnostics, and therefore, hematologic applications. To that end, per the NHLBI's U54 POCTRN guidelines, the overall goal of the Atlanta Center for Microsystems Engineered POC Technologies (ACME POCT) is to assist and enable inventors from across the country who have developed microsystems-based POC technologies for cardiac, pulmonary, hematologic and sleep applications that are beyond proof-of-concept to define their specific clinical needs, conduct clinical validation, and refine their technology, with the objective of accelerating the path to translation and clinical adoption and directly addressing the barriers thereof. The ACME POCT uniquely leverages Atlanta's nationally top-ranked clinical programs at Emory University's hospitals and Children's Healthcare of Atlanta, one of the nation's largest pediatric hospital systems, as well the internationally acclaimed microsystems engineering expertise at Georgia Tech, which includes the Institute for Electronics and Nanotechnology (IEN), and other one-of-a-kind medical device prototyping, innovation, and testbed facilities. The ACME POCT PI's uniquely balance the engineering and clinical sides of the Center and comprise Wilbur Lam, MD, PhD, a clinical hematologist at Emory and Georgia Tech bioengineer with expertise in POC diagnostic development and commercialization, Oliver Brand, PhD, a renowned microsystems engineer and head of Georgia Tech's IEN, and Greg Martin, MD, MSc, a clinical pulmonologist at Emory and head of clinical research in Atlanta's NIH-funded CTSA. Importantly, the leadership of the ACME POCT has a history of collaboration and track record in managing Centers that have fostered medical device development.", "keywords": [ "Address", "Adoption", "Ambulances", "American", "Bedside Testings", "Biomedical Engineering", "Blood", "COVID-19", "Cardiac", "Cardiology", "Care Technology Points", "Cellular Phone", "Child health care", "Clinical", "Clinical Research", "Clinical and Translational Science Awards", "Collaborations", "Country", "Critical Care", "Critical Illness", "Development", "Device or Instrument Development", "Devices", "Diagnosis", "Diagnostic", "Diagnostic tests", "Doctor of Philosophy", "Electronics", "Emergency Situation", "Engineering", "Equilibrium", "Fostering", "Funding", "Goals", "Guidelines", "Head", "Heart", "Heart Diseases", "Hematologist", "Hematology", "Home environment", "Hospitals", "Institutes", "International", "Leadership", "Lung", "Lung diseases", "Medical Device", "Medical Technology", "Microfluidics", "Monitor", "Movement", "Nanotechnology", "National Heart Lung and Blood Institute", "Organ", "Pathologic", "Pediatric Hospitals", "Physicians&apos", "Offices", "Play", "Population", "Pulmonology", "Recording of previous events", "Role", "Running", "Schools", "Side", "Signal Transduction", "Sleep", "System", "Technology", "Time", "Translations", "United States National Institutes of Health", "University Hospitals", "Validation", "Work", "base", "commercialization", "health care delivery", "innovation", "microchip", "microsystems", "novel", "point of care", "point-of-care diagnostics", "portability", "programs", "prototype", "public health relevance", "research clinical testing", "sensor", "sound" ], "approved": true } }, { "type": "Grant", "id": "7174", "attributes": { "award_id": "3U54EB027690-03S2", "title": "Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 6433, "first_name": "Tiffani Bailey", "last_name": "Lash", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-30", "end_date": "2022-05-31", "award_amount": 7085000, "principal_investigator": { "id": 15708, "first_name": "Oliver", "last_name": "Brand", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22968, "first_name": "Wilbur A", "last_name": "Lam", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22969, "first_name": "GREGORY S", "last_name": "MARTIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The advent of point-of-care (POC) diagnostic capabilities has enabled rapid and timely clinical evaluation in the physician's office, an ambulance, the home, the field, or in the hospital and has the potential to significantly impact health care delivery. In cardiology, pulmonology/critical care, and hematology, POC testing plays an especially significant role as the heart and lungs are among the most vital of organs necessitating real time diagnosis and rapid management during critical illnesses, while pathologic alternations in blood are associated with critical, systemic illness. One class of novel medical technologies that is showing promise for POC applications are microsystems-engineered technologies, that is, microchip-enabled devices ranging from microelectromechanical systems (MEMs)-based sensors, microfluidics, to even smartphone-based systems. Notable for their small size and power requirements, microchip-based systems provide the portability that is vital for POC testing. In addition, the capability of microsystems to convert sound and movement into electrical signals enable these technologies to be ideal devices to sense the dynamics of the lungs and heart and therefore to diagnose and monitor pulmonary and cardiac disorders. Moreover, microsystems engineering has brought forth the field of microfluidics, which is steadily finding applications for blood-based diagnostics, and therefore, hematologic applications. To that end, per the NHLBI's U54 POCTRN guidelines, the overall goal of the Atlanta Center for Microsystems Engineered POC Technologies (ACME POCT) is to assist and enable inventors from across the country who have developed microsystems-based POC technologies for cardiac, pulmonary, hematologic and sleep applications that are beyond proof-of-concept to define their specific clinical needs, conduct clinical validation, and refine their technology, with the objective of accelerating the path to translation and clinical adoption and directly addressing the barriers thereof. The ACME POCT uniquely leverages Atlanta's nationally top-ranked clinical programs at Emory University's hospitals and Children's Healthcare of Atlanta, one of the nation's largest pediatric hospital systems, as well the internationally acclaimed microsystems engineering expertise at Georgia Tech, which includes the Institute for Electronics and Nanotechnology (IEN), and other one-of-a-kind medical device prototyping, innovation, and testbed facilities. The ACME POCT PI's uniquely balance the engineering and clinical sides of the Center and comprise Wilbur Lam, MD, PhD, a clinical hematologist at Emory and Georgia Tech bioengineer with expertise in POC diagnostic development and commercialization, Oliver Brand, PhD, a renowned microsystems engineer and head of Georgia Tech's IEN, and Greg Martin, MD, MSc, a clinical pulmonologist at Emory and head of clinical research in Atlanta's NIH-funded CTSA. Importantly, the leadership of the ACME POCT has a history of collaboration and track record in managing Centers that have fostered medical device development.", "keywords": [ "Address", "Adoption", "Ambulances", "Bedside Testings", "Biomedical Engineering", "Blood", "Cardiac", "Cardiology", "Care Technology Points", "Cellular Phone", "Child health care", "Clinical", "Clinical Research", "Clinical and Translational Science Awards", "Clinical assessments", "Collaborations", "Country", "Critical Care", "Critical Illness", "Data", "Development", "Device or Instrument Development", "Devices", "Diagnosis", "Diagnostic", "Doctor of Philosophy", "Electronics", "Engineering", "Equilibrium", "Faculty", "Fostering", "Funding", "Future", "General Population", "Goals", "Guidelines", "Head", "Health Services Research", "Heart", "Heart Diseases", "Heart failure", "Hematologist", "Hematology", "Home environment", "Hospitals", "Institutes", "International", "Leadership", "Lung", "Lung diseases", "Medical Device", "Medical Technology", "Medicine", "Microfluidics", "Monitor", "Movement", "Nanotechnology", "National Heart Lung and Blood Institute", "Organ", "Pathologic", "Patients", "Pediatric Hospitals", "Physicians", "Physicians&apos", "Offices", "Play", "Process", "Pulmonology", "Recording of previous events", "Role", "Side", "Signal Transduction", "Sleep", "System", "Technology", "Testing", "Time", "Training Activity", "Translations", "United States National Institutes of Health", "University Hospitals", "Validation", "base", "commercialization", "cost", "health care delivery", "innovation", "microchip", "microsensor", "microsystems", "novel", "operation", "point of care", "point-of-care diagnostics", "portability", "programs", "prototype", "research clinical testing", "sensor", "sound", "success", "technology development", "technology training", "uptake", "usability" ], "approved": true } }, { "type": "Grant", "id": "9045", "attributes": { "award_id": "3U54EB027690-02S1", "title": "Emergency COVID-19 supplement for Atlanta Center for Microsystems Engineered Point-of-Care Technoloites (ACME POCT)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 6433, "first_name": "Tiffani Bailey", "last_name": "Lash", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-22", "end_date": "2021-05-21", "award_amount": 31080737, "principal_investigator": { "id": 15708, "first_name": "Oliver", "last_name": "Brand", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22968, "first_name": "Wilbur A", "last_name": "Lam", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22969, "first_name": "GREGORY S", "last_name": "MARTIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The advent of point-of-care (POC) diagnostic capabilities has enabled rapid and timely clinical evaluation in the physician's office, an ambulance, the home, the field, or in the hospital and has the potential to significantly impact health care delivery. In cardiology, pulmonology/critical care, and hematology, POC testing plays an especially significant role as the heart and lungs are among the most vital of organs necessitating real time diagnosis and rapid management during critical illnesses, while pathologic alternations in blood are associated with critical, systemic illness. One class of novel medical technologies that is showing promise for POC applications are microsystems-engineered technologies, that is, microchip-enabled devices ranging from microelectromechanical systems (MEMs)-based sensors, microfluidics, to even smartphone-based systems. Notable for their small size and power requirements, microchip-based systems provide the portability that is vital for POC testing. In addition, the capability of microsystems to convert sound and movement into electrical signals enable these technologies to be ideal devices to sense the dynamics of the lungs and heart and therefore to diagnose and monitor pulmonary and cardiac disorders. Moreover, microsystems engineering has brought forth the field of microfluidics, which is steadily finding applications for blood-based diagnostics, and therefore, hematologic applications. To that end, per the NHLBI's U54 POCTRN guidelines, the overall goal of the Atlanta Center for Microsystems Engineered POC Technologies (ACME POCT) is to assist and enable inventors from across the country who have developed microsystems-based POC technologies for cardiac, pulmonary, hematologic and sleep applications that are beyond proof-of-concept to define their specific clinical needs, conduct clinical validation, and refine their technology, with the objective of accelerating the path to translation and clinical adoption and directly addressing the barriers thereof. The ACME POCT uniquely leverages Atlanta's nationally top-ranked clinical programs at Emory University's hospitals and Children's Healthcare of Atlanta, one of the nation's largest pediatric hospital systems, as well the internationally acclaimed microsystems engineering expertise at Georgia Tech, which includes the Institute for Electronics and Nanotechnology (IEN), and other one-of-a-kind medical device prototyping, innovation, and testbed facilities. The ACME POCT PI's uniquely balance the engineering and clinical sides of the Center and comprise Wilbur Lam, MD, PhD, a clinical hematologist at Emory and Georgia Tech bioengineer with expertise in POC diagnostic development and commercialization, Oliver Brand, PhD, a renowned microsystems engineer and head of Georgia Tech's IEN, and Greg Martin, MD, MSc, a clinical pulmonologist at Emory and head of clinical research in Atlanta's NIH-funded CTSA. Importantly, the leadership of the ACME POCT has a history of collaboration and track record in managing Centers that have fostered medical device development.", "keywords": [ "Address", "Adoption", "Ambulances", "American", "Bedside Testings", "Biomedical Engineering", "Blood", "COVID-19", "Cardiac", "Cardiology", "Care Technology Points", "Cellular Phone", "Child health care", "Clinical", "Clinical Research", "Clinical and Translational Science Awards", "Collaborations", "Country", "Critical Care", "Critical Illness", "Development", "Device or Instrument Development", "Devices", "Diagnosis", "Diagnostic", "Diagnostic tests", "Doctor of Philosophy", "Electronics", "Emergency Situation", "Engineering", "Equilibrium", "Fostering", "Funding", "Goals", "Guidelines", "Head", "Heart", "Heart Diseases", "Hematologist", "Hematology", "Home environment", "Hospitals", "Institutes", "International", "Leadership", "Lung", "Lung diseases", "Medical Device", "Medical Technology", "Microfluidics", "Monitor", "Movement", "Nanotechnology", "National Heart Lung and Blood Institute", "Organ", "Pathologic", "Pediatric Hospitals", "Physicians&apos", "Offices", "Play", "Population", "Pulmonology", "Recording of previous events", "Role", "Running", "Schools", "Side", "Signal Transduction", "Sleep", "System", "Technology", "Time", "Translations", "United States National Institutes of Health", "University Hospitals", "Validation", "Work", "base", "commercialization", "health care delivery", "innovation", "microchip", "microsystems", "novel", "point of care", "point-of-care diagnostics", "portability", "programs", "prototype", "public health relevance", "research clinical testing", "sensor", "sound" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1405, "count": 14046 } } }